RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Active:	Yes
Cancer Type:	Solid Tumor	NCT ID:	NCT07002034
Trial Phases:	Phase II	Protocol IDs:	RE104-202-ADCO (primary) NCI-2025-04106
Eligibility:	18 - 80 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Reunion Neuroscience Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT07002034

Summary

The purpose of this study is to determine if treatment with a single dose of RE104 for
Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms
in participants with Adjustment Disorder due to cancer or other illnesses such as
Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or
Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.